Patents by Inventor Jennifer Lopansri

Jennifer Lopansri has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9592274
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 14, 2017
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9592273
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: March 14, 2017
    Assignee: SHIRE-NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9572867
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: February 21, 2017
    Assignee: Shire-NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170028028
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: February 2, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170028024
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: February 2, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170028025
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: February 2, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170028026
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: February 2, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170028030
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: February 2, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170028027
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: February 2, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170028029
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: February 2, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • Treatment of short bowel syndrome patients with colon-in-continuity
    Patent number: 9555079
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Grant
    Filed: October 5, 2016
    Date of Patent: January 31, 2017
    Assignee: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020969
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020983
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020973
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020971
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020989
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020988
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020967
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS Pharmaceuticals, Inc.
    Inventors: Elizabeth L. Sanguinetti, Thomas B. Marriott, Jennifer Lopansri, Consuelo M. Blosch
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020970
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH
  • TREATMENT OF SHORT BOWEL SYNDROME PATIENTS WITH COLON-IN-CONTINUITY
    Publication number: 20170020984
    Abstract: Intestinal absorption is enhanced in short bowel syndrome patients presenting with colon-in-continuity by treatment with a GLP-2 receptor agonist, such as teduglutide.
    Type: Application
    Filed: October 5, 2016
    Publication date: January 26, 2017
    Applicant: NPS PHARMACEUTICALS, INC.
    Inventors: Elizabeth L. SANGUINETTI, Thomas B. MARRIOTT, Jennifer LOPANSRI, Consuelo M. BLOSCH